LOGIN  |  REGISTER

Doximity to Release Fiscal 2026 First Quarter Results on August 7, 2025

July 17, 2025 | Last Trade: US$72.57 0.96 -1.31

SAN FRANCISCO / Jul 17, 2025 / Business Wire / Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2025 after market close on August 7, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results.

To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call.

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.

Recursion

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page